top of page
it's where dermatology lives


press to zoom

press to zoom

press to zoom
1/2


VIDEO: Vitamin B5 derivative may be potential treatment for PsO
Patients taking tablets containing a vitamin B5 derivative known as pantethine experienced improved psoriasis symptoms
Jeremy Visser
3 days ago1 min read


VIDEO: Tildrakizumab linked to epigenetic age deviation in PsO patients
PsO patients treated with tildrakizumab saw a reversal of epigenetic aging.
Jeremy Visser
Oct 71 min read


VIDEO: Zasocitinib effective in treating PsO in hard-to-treat areas
Zasocitinib is effective in improving skin clearance for PsO patients in hard-to-treat areas with once-daily treatment
Jeremy Visser
Aug 191 min read


AI-guided CRISPR study identifies potential topical psoriasis treatments
An AI-guided network analysis of genomic data (left) highlights two protein targets, including the oxytocin receptor, identified through Biohub’s CRISPR screen in primary human skin cells (right). Image by Zhao, C., Shih, M., Ahmed, S. et al. Nat Commun (2026). Researchers have combined genome-wide CRISPR screening with artificial intelligence to identify two unexpected therapeutic targets for psoriasis, opening a possible path toward topical treatments that avoid systemic im
Allan Ryan
Aug 102 min read


VIDEO: GLP-1 receptor agonists may be effective as adjunct therapy for skin diseases
GLP-1 receptor agonists may have potential applications as adjunct therapy for PsO, AD, HS, chronic wounds, and other skin conditions.
Jeremy Visser
Jul 221 min read


VIDEO: PsO patients trust topicals less than AD patients
Trust levels regarding topical therapy were higher among AD patients than PsO patients
Jeremy Visser
Jun 171 min read


VIDEO: Text message intervention effective in improving cardiovascular risk in PsO patients
A text message intervention system improved cardiovascular risk behaviours and patient confidence managing their health in adult psoriasis patients
Jeremy Visser
Jun 101 min read


Guselkumab offers long-term safety in all skin types
All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle
Allan Ryan
Jun 83 min read
Featured Posts


bottom of page
